Pasithea Therapeutics Corp. (NASDAQ: KTTA) — Point-in-Time Research Snapshot (as of 2026-10-31)

Company basics: Pasithea is a clinical-stage biotech on the NASDAQ Capital Market developing PAS-004, a next-generation macrocyclic oral MEK inhibitor targeting RASopathies (including NF1), MAPK pathway-driven tumors, and other diseases (CNS disorders, ETS2-driven diseases like ID) [2], [7], [18]. As of 2026-10-31, it is a micro-capitalization company (~$12.37M market cap), pre-revenue, with a stock price around $0.37 and net losses of roughly -$20 to -$21M over the trailing year [18], [19].

---

Key Recent Catalysts (last ~1–3 months)